Silence Therapeutics plc Overview
Pro stress-test →Silence Therapeutics is a global clinical-stage biotechnology company committed to transforming people's lives by silencing diseases through precision engineered medicines created with proprietary siRNA (short interfering RNA) technology. The company leverages its mRNAi GOLD™ platform to create innovative siRNAs designed to precisely target and silence disease-associated genes in the liver.
Strategic Profile
Pro stress-test →Silence focuses on areas of high unmet medical need with programs advancing in cardiovascular disease, hematology and rare diseases. The company has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Hansoh Pharmaceutical Group Company Limited to develop siRNAs.
Competitive Landscape
Pro stress-test →Silence Therapeutics is a biotechnology company and leader dedicated in the discovery, development and delivery of novel RNA interference (RNAi) therapeutics for the treatment of serious diseases. The company competes in the siRNA therapeutic space alongside other RNAi developers and traditional pharma, differentiated by its proprietary mRNA GOLD platform and delivery technology. Strategic partnerships with major pharma like AstraZeneca enhance competitive positioning.
Industry Context
Silence Therapeutics plc operates in Biotechnology - RNA Therapeutics / Genetic Medicine.
Key facts
Founded: 1994 · Headquarters: London, United Kingdom · Market cap: $287M (as of March 2026)